Загрузка...
Activity-based protein profiling shows heterogeneous signaling adaptations to BRAF inhibition
Patients with BRAF V600E mutant melanoma are typically treated with targeted BRAF kinase inhibitors, such as vemurafenib and dabrafenib. Although these drugs are initially effective, they are not curative. Most of the focus to date has been upon genetic mechanisms of acquired resistance; therefore,...
Сохранить в:
| Опубликовано в: : | J Proteome Res |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5642956/ https://ncbi.nlm.nih.gov/pubmed/27934295 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jproteome.6b00613 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|